
![]()
Comunicados de Prensa México
México, D.F. a 26 de Febrero de 2008
- First study to show Diovan/HCT improves artery elasticity in
patients with type 2 diabetes, high blood pressure and kidney disease[1]
- Diovan/HCT demonstrated superior benefits on artery
elasticity, a strong predictor of increased risk of stroke and heart
attack[2], compared to amlodipine
- Diovan/HCT lowered albumin excretion rate, a key marker of kidney disease, by 35% compared to a rise of 24% with amlodipine[1]
- Diovan is the world's number one branded high blood pressure medicine[3]

